BioSpace News Archive

Kerecis and the National Hospital of Iceland are conducting a randomized, controlled, double-blind clinical study to evaluate the effectiveness of the Kerecis Omega3 Viruxide system on COVID-19 patients

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will virtually present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 2:10 p.m. ET.

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive Offer at Iterum Therapeutics, will provide a company overview and business update at the 19th Annual Needham Virtual Healthcare Conference

Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter Fiscal 2020 on Thursday, May 7, 2020, prior to the opening of trading on the New York Stock Exchange.

Phathom Pharmaceuticals, Inc. announced that company management will participate in one-on-one meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.

Braingrid Limited, and European High Growth Opportunities Securitization Fund have entered into a shares for debt settlement agreement, pursuant to which EHGOSF has agreed, subject to the Canadian Securities Exchange approval, to accept 78,300,000 common shares of the Company, at a deemed issued price of $0.01 per Share, in full settlement of $783,000 of indebtedness owing to EHGOSF by the Company.

Adaptive Biotechnologies, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the addition of two prominent hires to its executive leadership team.

Active Motif announced the successful isolation of antibodies from patients in China recovering from 2019 Coronavirus related pneumonia.

Samsung Biologics and Vir Biotechnology, Inc. announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir’s SARS-CoV-2 monoclonal antibody program..